Skip to main content

Table 3 Vaccine Clinical Trials and Mechanisms in PDAC

From: Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma

NCT Number Status Immunogen Condition Mechanism Phase
NCT02405585 Terminated Algenpantucel-L vaccine Mfolfirinox, radiation and gemcitabine Human pancreatic cancer cells engineered with a mouse Algenpantucel-L gene to make the cancer cells foreign Phase 2
NCT01072981 Completed Algenpantucel-L vaccine Gemcitabine or 5FU chemoradiation Human pancreatic cancer cells engineered with a mouse Algenpantucel-L gene to make the cancer cells foreign Phase 3
NCT01836432 Unknown Algenpantucel-L vaccine FOLFIRINOX,
5-FU chemoradiation, gemcitabine, capecitabine, NabPaclitaxel
Human pancreatic cancer cells engineered with a mouse Algenpantucel-L gene to make the cancer cells foreign Phase 3
NCT03114631 Enrolling by invitation Dendritic cells pulsed with tumour lysate,
dendritic cells pulsed with MUC-1/WT-1 peptides
NO Increase MUC1/WT1-specific T cell response Phase 1
Phase 2
NCT00547144 Completed Intratumoural autologous dendritic cell vaccination Gemcitabine and stereotactic radiosurgery Increase tumour-specific T cells Phase 2
NCT00795977 Unknown Intratumoural autologous dendritic cell vaccination in combination with OK-432 NO Induce tumour antigen-specific T cell response and tumour festering reaction Phase 1
Phase 2
NCT03136406 Active, not recruiting GI-4000 Cyclophosphamide, oxaliplatin, capecitabine, fluorouracil, leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK, and ETBX-011 Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins to induce the Ras protein-specific reaction Phase 1
Phase 2
NCT03329248 Active, not recruiting GI-4000 ETBX-011, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin and 4 more Induce mutant Ras protein-specific antitumour reaction Phase 1
Phase 2
NCT03387098 Active, not recruiting GI-4000 Aldoxorubicin HCl, ALT-803, ETBX-011, haNK for infusion, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil and 5 more Induce mutant Ras protein-specific antitumour reaction Phase 1
Phase 2
NCT00837135 Withdrawn GI-4000 Activated T cells Induce mutant Ras protein-specific antitumour reaction Phase 1
NCT00002773 Completed Allogeneic tumour cell vaccine Recombinant IFNγ, sargramostim and cyclophosphamide Induce tumour-specific reaction between patients sharing some TSAs Phase 2
NCT00003025 Completed HSPPC-96 NO Autologous tumour-derived pg96 heat shock protein complex to induce an antitumour reaction Phase 1
NCT00003434 Terminated Autologous DC pulsed with a mutated CEA epitope-CAP-1 NO Induce CAP-1-specific antitumour T cell reaction Phase 1
NCT00669734 Active, not recruiting Falimarev Sargramostim A cancer vaccine comprised of a recombinant fowlpox viral vector encoding CEA, MUC-1 to induce CEA- and MUC1-specific antitumour reactions Phase 1
NCT02338752 Completed MV (mixed vaccines) Standard treatment An intravenous intralipid suspension with 5 various vaccines, including DPT, typhoid, Staphylococcus aureus, and paratyphoid A and B Phase 1
Phase 2
NCT03153410 Recruiting GVAX Cyclophosphamide, pembrolizumab, IMC-CS4 Pancreatic cell lines secreting GM-CSF to induce DC maturation Early phase 1
NCT02648282 Recruiting GVAX Cyclophosphamide, pembrolizumab and radiation Pancreatic cell lines secreting GM-CSF to induce DC maturation Phase 2
NCT03161379 Recruiting GVAX Cyclophosphamide, nivolumab and radiation Pancreatic cell lines secreting GM-CSF to induce DC maturation Phase 2
NCT01896869 Suspended GVAX Ipilimumab, FOLFIRINOX Pancreatic cell lines secreting GM-CSF to induce DC maturation Phase 2
NCT00836407 Completed GVAX Ipilimumab Pancreatic cell lines secreting GM-CSF to induce DC maturation Phase 1
NCT01417000 Completed GVAX and CRS-207 Cyclophosphamide Pancreatic cell lines secreting GM-CSF to induce DC maturation in combination with a recombinant live-attenuated Listeria monocytogenes strain engineered to secrete mesothelin into the cytoplasm of infectious APCs Phase 2
NCT03190265 Recruiting GVAX and CRS-207 Cyclophosphamide, nivolumab, ipilimumab Increase the mesothelin-specific antitumour activity and enhance the antigen-presenting ability of APCs Phase 2
NCT02004262 Completed GVAX and CRS-207 Cyclophosphamide Increase the mesothelin-specific antitumour activity and enhance the antigen-presenting ability of APCs Phase 2
NCT03006302 Recruiting GVAX and CRS-207 Epacadostat, pembrolizumab, cyclophosphamide Increase the mesothelin-specific antitumour activity and enhance the antigen-presenting ability of APCs Phase 2
NCT02960594 Completed INO-1400; INO-1401 INO-9012: a DNA molecule (plasmid) encoding IL-12 A synthetic telomerase reverse transcriptase (TERT) DNA vaccine to induce TERT-specific antitumour reaction Phase 1
NCT00128622 Completed Autologous dendritic cells infected with recombinant fowlpox-CEA(6D)-TRICOM vaccine Denileukin diftitox DCs were mixed with recombinant fowlpox-TRICOM to produce the vaccine and induce a CEA-specific antitumour reaction Phase 1
NCT00529984 Completed AVX701 NO CEA(6D) VRP vaccine to induce a CEA-specific immune response targeting the mutated CEA epitope -CAP-1(6D) Phase 1
Phase 2
NCT03552718 Recruiting YE-NEO-001 NO Recombinant yeast vaccine engineered to express multiple neoepitopes based on individual tumour molecular profiles Phase 1
NCT00245362 Completed CG 8020 and CG 2505 NO Allogeneic
cancer cell lines
engineered to secrete GM-CSF to enhance the antigen-presenting ability of DCs
Phase 2
NCT00019084 Completed Mutant p53 peptide- or ras peptide-pulsed APCs GM-CSF, mutated peptide-stimulated autologous lymphocytes or TILs APCs pulsed with synthetic version of the patient’s mutated p53 or ras peptide to induce a mutated peptide-specific antitumour reaction Phase 2
NCT00002475 Completed Allogeneic or autologous tumour cell vaccine Recombinant IFN α, recombinant interferon γ, sargramostim, cyclophosphamide Induce an adaptive immune reaction Phase 2
NCT00027534 Completed Autologous dendritic cells infected with recombinant fowlpox-CEA-TRICOM vaccine NO Increase the CEA-specific immune response Phase 1
NCT00004604 Completed CEA RNA-pulsed DC cancer vaccine NO Increase the CEA-specific immune response Phase 1
NCT02151448 Active, not recruiting Autologous alpha-DC1 loaded with autologous tumour material Celecoxib, IFNα-2b, rintatolimod Increase the adaptive antitumour response Phase 1
Phase 2
NCT03300843 Recruiting DC vaccine with defined immunogenic neoepitopes NO Induce a personalized mutated neoantigen immune response Phase 2
NCT01088789 Recruiting PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine With or without cyclophosphamide Increase the antitumour cellular response Phase 2
NCT01595321 Active, not recruiting PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine Cyclophophamide, radiation, FOLFIRINOX Increase the antitumour cellular response Not applicable
NCT01342224 Completed GV1001 Immune adjuvant, GM-CSF, gemcitabine A telomerase vaccine Phase 1